Steward Partners Investment Advisory’s PTC Therapeutics PTCT Stock Holding History

Steward Partners Investment Advisory’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-588	Closed	-$22K	–	3291
2021 Q3	$22K	Hold	588	–	–	﹤0.01%	2286
2021 Q2	$25K	Hold	588	–	–	﹤0.01%	4728
2021 Q1	$27.8K	Hold	588	–	–	﹤0.01%	2306
2020 Q4	$36K	Hold	588	–	–	﹤0.01%	1826
2020 Q3	$27K	Hold	588	–	–	﹤0.01%	1779
2020 Q2	$30K	Buy	588 +294	+100%	+$14.4K	﹤0.01%	1616
2020 Q1	$13K	Buy	+294	New	+$14.8K	﹤0.01%	1765

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Steward Partners Investment Advisory's PTCT Position: Q4 2021 in Review

Steward Partners Investment Advisory sold out of PTC Therapeutics (PTCT) in Q4 2021, closing a stake of 588 shares — an estimated $22K sold.

Steward Partners Investment Advisory first reported a position in PTCT in Q1 2020 and held it in 7 quarters. The position peaked at $36K in Q4 2020. 178 funds tracked by Wall St. Rank hold PTCT as of Q4 2021.

Steward Partners Investment Advisory reported no remaining PTC Therapeutics position as of Q4 2021 after selling out during the quarter.
Steward Partners Investment Advisory sold 588 PTC Therapeutics shares in Q4 2021, an estimated $22K.
Steward Partners Investment Advisory first reported a position in PTC Therapeutics in Q1 2020 and held it in 7 quarters.
Steward Partners Investment Advisory's PTC Therapeutics position peaked at $36K in Q4 2020.
178 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2021, filed 8 Feb 2022.